Expectations for Methodology and Translation of Animal Research: A Survey of Health Care Workers by Joffe, Ari et al.
WellBeing International 
WBI Studies Repository 
5-7-2015 
Expectations for Methodology and Translation of Animal 
Research: A Survey of Health Care Workers 
Ari Joffe 
University of Alberta 
Meredith Bara 
University of Alberta 
Natalie Anton 
University of Alberta 
Nathan Nobis 
Morehouse College 
Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/acwp_arte 
 Part of the Animal Experimentation and Research Commons, Animal Studies Commons, and the 
Design of Experiments and Sample Surveys Commons 
Recommended Citation 
Joffe, A. R., Bara, M., Anton, N., & Nobis, N. (2015). Expectations for methodology and translation of 
animal research: a survey of health care workers. BMC medical ethics, 16(1), 29. 
This material is brought to you for free and open access 
by WellBeing International. It has been accepted for 
inclusion by an authorized administrator of the WBI 
Studies Repository. For more information, please contact 
wbisr-info@wellbeingintl.org. 
RESEARCH ARTICLE Open Access
Expectations for methodology and translation of
animal research: a survey of health care workers
Ari R Joffe1,2*, Meredith Bara3, Natalie Anton1 and Nathan Nobis4,5
Abstract
Background: Health care workers (HCW) often perform, promote, and advocate use of public funds for animal research
(AR); therefore, an awareness of the empirical costs and benefits of animal research is an important issue for HCW. We
aim to determine what health-care-workers consider should be acceptable standards of AR methodology and translation
rate to humans.
Methods: After development and validation, an e-mail survey was sent to all pediatricians and pediatric intensive care
unit nurses and respiratory-therapists (RTs) affiliated with a Canadian University. We presented questions about
demographics, methodology of AR, and expectations from AR. Responses of pediatricians and nurses/RTs were
compared using Chi-square, with P < .05 considered significant.
Results: Response rate was 44/114(39%) (pediatricians), and 69/120 (58%) (nurses/RTs). Asked about methodological
quality, most respondents expect that: AR is done to high quality; costs and difficulty are not acceptable justifications
for low quality; findings should be reproducible between laboratories and strains of the same species; and guidelines
for AR funded with public money should be consistent with these expectations. Asked about benefits of AR, most
thought that there are sometimes/often large benefits to humans from AR, and disagreed that “AR rarely produces
benefit to humans.” Asked about expectations of translation to humans (of toxicity, carcinogenicity, teratogenicity, and
treatment findings), most: expect translation >40% of the time; thought that misleading AR results should occur <21%
of the time; and that if translation was to occur <20% of the time, they would be less supportive of AR. There were few
differences between pediatricians and nurses/RTs.
Conclusions: HCW have high expectations for the methodological quality of, and the translation rate to humans of
findings from AR. These expectations are higher than the empirical data show having been achieved. Unless these
areas of AR significantly improve, HCW support of AR may be tenuous.
Keywords: Animal models, Animal research, Ethics, Methodology
Background
Biomedical animal research (AR) involves some harm to
sentient animals including distress (due to confinement,
boredom, isolation, and fear), pain, and early death [1-3].
AR is said to be morally permissible because the balance
of these costs (harms to the animals) and benefits (to
human medical care, quality of life, and survival) is fa-
vorable [4]. It is generally assumed that the benefits are
great to human medicine [5]. An awareness of the
empirical costs and benefits of AR is an important issue
in medicine for several reasons. Health care workers
(HCW) often perform (and are expected to perform)
AR, promote AR directly with trainees and indirectly as
role models, and advocate for use of public funds (from
granting agencies and charitable foundations) toward
medical related AR.
There is a growing literature that raises concerns about
the empirical practice of AR in at least two domains. First,
the methodological quality of AR is often poor in both ex-
perimental design and animal welfare aspects [6-12]. AR
publications rarely report the use of eligibility criteria,
randomization, allocation concealment, blinding, sample
size calculation, primary outcome specification, and study
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replication [6-10,13,14]. AR publications rarely report per-
forming a systematic review to determine the necessity of
the research project, rarely report the use of continuous
monitoring of the level of anesthesia or pain control, and
often do not report the use of acceptable methods of eu-
thanasia [7,11,12]. Second, the translation rate from AR to
humans has been disappointing [15-18]. Extensive AR in
the fields of sepsis [19-21], stroke [22,23], spinal cord in-
jury [24,25], traumatic brain injury [26], cancer [27,28],
degenerative neurological diseases [29,30], acquired im-
munodeficiency syndrome [31], asthma [32], and other
fields [15-18] has translated to humans in 0-5% of cases.
Pharmaceutical companies have found that, of drugs that
work well in AR and progress to human clinical trials,
only ≤8% are found safe and effective enough for market
approval [33,34]. AR to determine toxicology [17,35-37],
carcinogenicity [17,37-39], and teratogenicity [17,40] of
drugs or compounds is no more accurate than chance,
with concordance rates between species generally <40%.
Since most AR is funded by public money through
government and charitable granting agencies, it is im-
portant to know the public perception of, and the level
of public support for AR. Surveys of the public find that
the majority are ‘conditional acceptors’ of AR; they
accept the practice because of the promise of cures and
treatments for life-threatening and debilitating human
diseases, so long as animal welfare is at least minimally
considered and protected [41]. To our knowledge, no
survey has asked for the details of this conditional ac-
ceptance of AR. In this survey we ask HCW directly
what the minimal acceptable standards in AR method-
ology might be, and what the minimal acceptable trans-
lation rate of AR to human treatments might be. This is
important in order to determine how strong the support
is for the empirical practice of AR, and how AR could
be improved to increase the level of support. We found
that HCW have high expectations for the methodo-




All pediatricians and pediatric intensive care unit nurses
and respiratory therapists (RTs) who are affiliated with
one Canadian University were e-mailed the survey using
an electronic, secure, survey distribution and collection
system (REDCap, Research Electronic Data Capture)
[42]. A cover letter stated that “we very much value your
opinion on this important issue” and that the survey was
anonymous and voluntary. We offered the incentive that
if the response rate was at least 70% we would donate
$1000 to the Against Malaria Foundation or the PICU
Social Committee. Non-responders were sent the survey
by e-mail at 3-week intervals for 3 additional mailings.
Questionnaire development
We followed published recommendations [43]. To gener-
ate the items for the questionnaire, we searched Medline
from 1980 to 2012 for articles about the methodology and
translation of AR. This was followed by collaborative cre-
ation of the background section and questions for the sur-
vey by the authors. Content and construct validation were
done using a table of specifications filled out by experts
including two ethics philosophy professors, and two pe-
diatricians. Face and content validation were done by
pilot testing of the survey, by non-medical, university-
educated lay people (n = 9), pediatricians (n = 2),
pediatric intensive care nurses (n = 2), and an ethics
professor (n = 1). Each pilot test was followed by a semi-
structured interview by 1 of the authors to ensure clar-
ity, realism, validity, and ease of completion. A published
clinical sensibility tool was used for the expert and pilot
testing [43]. After minor modifications, the survey was
approved by all the authors.
Questionnaire content
The background section stated: “In this survey, ‘animals’
means: mammals, such as mice, rats, dogs, and cats. It
has been estimated that over 100 million animals are
used in the world for research each year. There are many
good reasons to justify AR, which is the topic of this sur-
vey. Nevertheless, some people argue that these animals
are harmed in experimentation, because their welfare is
worsened. In this survey, ‘harmful’ means such things as:
pain, suffering (disease/injury, boredom, fear, confine-
ment), and early death. This survey is about how AR
should be performed. We value your opinion on the very
important issue of the methodology of AR.”
We presented demographic questions, 15 questions that
asked respondents “about the methods of AR that are
commonly discussed by animal researchers”, 4 questions
that asked the respondent “to consider what you think the
benefits to humans are as a result of AR”, and 8 questions
that asked the respondent “for your opinions about what
you expect from AR paid for with public funds (for ex-
ample, funding by government using tax dollars, or charit-
able foundations using donations).” Response choices
included scales of “strongly agree, agree, undecided, dis-
agree, strongly disagree”, “nearly always, often, sometimes,
not often, almost never”, and “5-20%, 21-40%, 41-60%, 61-
80%, over 80%” depending on the type of question. All the
questions are shown in the Tables 1, 2, 3, and 4.
Ethics approval
The study was approved by the health research ethics
board 2 of our university (study ID Pro00039590) and
return of a survey was considered consent to participate.
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Statistics
The web-based tool (REDCap) allows anonymous survey
responses to be collected, and later downloaded into an
SPSS database for analysis. The proportions of respon-
dents with different answers were expressed as percent-
ages. The responses of the two predefined groups,
pediatricians and pediatric intensive care unit nurses/
RTs, were compared using the Chi-square statistic, with





Forty-eight responded, but only 44/114 (39%) gave re-
sponses to more than the demographic questions.
Demographics are given in Table 1.
Expectations regarding methodology of AR
The majority of respondents agreed that: anesthetic use
should be monitored during surgery (100%), pain should
be monitored after this surgery even over-night (91%),
and experimenters in a research study should have simi-
lar training on the procedures involved (97%) (Table 2).
The majority disagreed that it is acceptable: to use less
humane methods of euthanasia to reduce costs or im-
prove results (82% or 52% respectively), to use animals
when alternatives are available (73%), to do an animal
experiment without a systematic literature review
(100%), and to do an animal experiment using subopti-
mal methods (including randomization, blinding, and
primary outcome specification) in order to save costs
(82-93%). Only a minority of respondents agreed that
failed animal models of a disease should continue to be
used (30%), or that stressed animals should be used
(37%). Finally, the majority agreed that guidelines
consistent with these responses should be required for
publicly funded AR (95%).
Perceptions of human benefits from AR
Most respondents believe that discoveries from AR
sometimes or often lead to a treatment for human dis-
ease directly (77%) or indirectly (84%), and that re-
searchers sometimes or often claim large benefits from
AR (91%) (Table 3). The majority did not agree (84%)
with the statement that “AR rarely produces benefits to
humans.”
Expectations for translation to humans from AR paid for
with public funding
The majority of respondents think that drugs tested on
animals should correctly predict the following for
humans at least 41% of the time: adverse reactions (69%
of respondents), disease treatment (62% of respondents),
carcinogenicity or teratogenicity (74% of respondents),
and treatment of stroke, severe infection, cancer, brain
or spinal cord injury (59% of respondents). The majority
also expected that replication of AR findings in second
laboratories or other strains of the animal should occur
at least 61% of the time (95% and 68% of respondents
respectively). The majority agreed that misleading (in
terms of human benefit and/or harm) animal experi-
ments should occur at most 40% of the time (86% of re-
spondents). Finally, when asked to “assume drugs
studied in animals accurately predict effects in humans
less than 20% of the time. If this were true, it would sig-
nificantly reduce your support for animal research”, 40%
disagreed (Table 4).
Pediatric Intensive Care nurses and RTs
Demographics
Sixty-nine of 120 (58%) responded; 52 (75%) nurses and
16 (25%) RTs. Demographics are given in Table 1.
Expectations regarding methodology of AR
The majority of respondents agreed that: anesthetic use
should be monitored during surgery (98%), pain should
be monitored after this surgery even over-night (96%),
and experimenters in a research study should have simi-
lar training on the procedures involved (96%) (Table 2).
The majority disagreed that it is acceptable: to use less
humane methods of euthanasia to reduce costs or im-
prove results (87% or 81%), to use animals when alterna-
tives are available (88%), to do an animal experiment
without a systematic literature review (96%), and to do an
animal experiment using suboptimal methods (including
randomization, blinding, and primary outcome specifica-
tion) in order to save costs (87-95%). Only a minority of
respondents agreed that failed animal models of a disease
should continue to be used (27%), or that stressed animals






18-24 yr - 4 (7%)
25-34 yr 3 (6%) 38 (55%)
35-44 yr 16 (33%) 15 (22%)
45-54 yr 17 (35%) 8 (12%)
>54 yr 12 (25%) 3 (4%)
Sex (Male) 26 (54%) 7 (10%)
AR Experience
Have done AR experiments in past 25 (52%) 2 (3%)
Currently do AR 4 (8%) 0 (0%)
Have never done AR 19 (40%) 67 (97%)
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Table 2 Healthcare Worker expectations regarding the methodology used in Animal Research
Statement about methodology Respondent group Strongly agree Agree Uncertain Disagree Strongly disagree
Anesthetic used should be monitored (to ensure a deep enough level of anesthetic) during surgery on an animal in an experiment.
Pediatricians 30/44 (68%) 14/44 (32%) 0 0 0
Nurses/RTs 51/67 (76%) 15/67 (22%) 1/67 (2%) 0 0
Pain should be monitored after this surgery (to ensure comfort) so that adequate pain medications are given if the animal is in pain.
Pediatricians 29/44 (66%) 14/44 (32%) 1/44 (2%) 0 0
Nurses/RTs 49/68 (72%) 18/68 (27%) 1/68 (2%) 0 0
Pain should be monitored after this surgery even over-night (to ensure comfort) so that adequate pain medications are given if the animal is in pain.
Pediatricians 26/44 (59%) 14/44 (32%) 3/44 (7%) 1/44 (2%) 0
Nurses/RTs 49/68 (72%) 17/68 (25%) 1/68 (2%) 1/68 (2%) 0
When an animal is killed at the end of the experiment, it is acceptable to use a cheaper but less humane method of killing to reduce cost.
Pediatricians 0 2/44 (5%) 6/44 (14%) 10/44 (23%) 26/44 (59%)
Nurses/RTs 0 2/68 (3%) 7/68 (10%) 14/68 (21%) 45/68 (66%)
When an animal is killed at the end of the experiment, it is acceptable to use a less humane method of killing if this will improve the experimental
results.
Pediatricians 1/44 (2%) 9/44 (21%) 11/44 (25%) 11/44 (25%) 12/44 (27%)
Nurses/RTs 1/68 (2%) 7/68 (10%) 5/68 (7%) 15/68 (22%) 40/68 (59%)
To save time and money, it is acceptable to do an animal experiment even if there is another way to look at the experimental question that would
not require using animals.
Pediatricians 0 5/44 (11%) 7/44 (16%) 17/44 (39%) 15/44 (34%)
Nurses/RTs 0 5/68 (7%) 3/68 (4%) 19/68 (28%) 41/68 (60%)
To save time and money, it is acceptable to do an animal experiment using more animals even if statistical experts know of another way to look at
the experimental question that requires using fewer animals.
Pediatricians 0 3/44 (7%) 3/44 (7%) 19/ 44(43%) 19/44 (43%)
Nurses/RTs 0 6/68 (9%) 1/69 (2%) 21/68 (31%) 40/68 (59%)
To save time and money, it is acceptable to do an animal experiment without doing a comprehensive literature review that would determine if the
study has already been done by another research group.
Pediatricians 0 0 0 12/44 (27%) 32/44 (73%)
Nurses/RTs 0 1/68 (2%) 1/68 (2%) 21/68 (31%) 45/68 (66%)
It is acceptable to follow a research method that gives less reliable results in order to avoid the added costs of consulting an expert in study design.
Pediatricians 0 3/44 (7%) 2/44 (5%) 10/44 (23%) 29/44 (66%)
Nurses/RTs 0 0 2/68 (3%) 31/68 (46%) 35/68 (52%)
It is acceptable to follow a research method that gives less reliable results in order to avoid the added costs of hiring more laboratory staff.
Pediatricians 0 3/44 (7%) 5/44 (11%) 16/44 (36%) 20/44 (46%)
Nurses/RTs 0 0 3/67 (5%) 31/67 (46%) 33/67 (49%)
If an animal model of a disease has consistently found that successful treatments in animals have failed to work in humans, it is still acceptable to
use that animal model to test a different treatment for that disease.
Pediatricians 0 13/44 (30%) 12/44 (27%) 10/44 (23%) 9/44 (21%)
Nurses/RTs 1/68 (2%) 17/68 (25%) 17/68 (25%) 18/68 (27%) 15/68 (22%)
Some animal care practices result in stressed animals, which can have effects on their immune system and behavior. It is still acceptable to use these
animal care practices in research looking at how a new treatment affects the immune system and behavior.
Pediatricians 1/43 (2%) 15/43 (35%) 5/43 (12%) 12/43 (28%) 10/43 (23%)
Nurses/RTs 2/68 (3%) 11/68 (16%) 13/68 (19%) 16/68 (24%) 26/68 (38%)
If several experimenters are involved in an animal research study, they should each have similar training so they perform the procedures and
treatments consistently.
Pediatricians 19/42 (45%) 22/42 (52%) 0 0 1/42 (2%)
Nurses/RTs 36/67 (54%) 29/67 (43%) 1/67 (2%) 0 1/67 (2%)
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should be used (19%). Finally, the majority agreed that
guidelines consistent with these responses should be re-
quired for publicly funded AR (91%).
Perceptions of the benefits to humans from AR
Most respondents believe that discoveries from AR
sometimes or often lead to a treatment for human dis-
ease directly (84%) or indirectly (88%), and that re-
searchers sometimes or often claim large benefits from
AR (97%) (Table 3). The majority did not agree (87%)
with the statement that “AR rarely produces benefits to
humans.”
Expectations for translation to humans from AR paid for
with public funding
The majority of respondents think that drugs tested on
animals should correctly predict the following for
humans at least 41% of the time: adverse reactions (85%
of respondents), disease treatment (82% of respondents),
carcinogenicity or teratogenicity (89% of respondents),
and treatment of stroke, severe infection, cancer, brain
or spinal cord injury (88% of respondents). The majority
also expected that replication of AR findings in second
laboratories or other strains of the animal should occur
at least 61% of the time (92% and 83% of respondents
respectively). The majority agreed that misleading (in
terms of human benefit and/or harm) animal experi-
ments should occur at most 40% of the time (84% of re-
spondents). Finally, when asked to “assume drugs
studied in animals accurately predict effects in humans
less than 20% of the time. If this were true, it would sig-
nificantly reduce your support for animal research”, only
6% disagreed (Table 4).
Differences between pediatricians versus nurses/RTs
There were few statistically significant differences.
Nurses more often responded that drugs for stroke, se-
vere infection, cancer, brain or spinal cord injury should
Table 2 Healthcare Worker expectations regarding the methodology used in Animal Research (Continued)
Some research methods are important to getting reliable results, such as: deciding the most important result to be looked for, choosing animals for
each treatment at random, and measuring results without knowing which treatment each animal received. It is acceptable not to follow any of these
methods because of the added costs.
Pediatricians 0 3/43 (7%) 0 15/43 (35%) 25/43 (58%)
Nurses/RTs 2/68 (3%) 0 7/68 (10%) 18/68 (27%) 41/68 (60%)
For animal research paid for with public funds (for example, funding by government using tax dollars, or charitable foundations using donations),
guidelines consistent with your answers above should be required.
Pediatricians 19/42 (45%) 21/42 (50%) 2/42 (5%) 0 0
Nurses/RTs 32/68 (47%) 30/68 (44%) 5/68 (7%) 1/68 (2%) 0
There were no statistically significant differences in responses between pediatricians and nurses/RTs on any of these questions.
Table 3 Healthcare Worker perception of the benefits to humans from animal research
Statement about possible benefits
Respondent group Nearly always Often Sometimes Not often Almost never
How often do you think that a treatment discovered in animal research works in humans (a direct benefits to humans)?
Pediatricians 0 12/43 (28%) 21/43 (49%) 7/43 (16%) 3/43 (7%)
Nurses/RTs 0 22/68 (32%) 35/68 (52%) 10/68 (15%) 1/68 (2%)
How often do you think a discovery in animal research contributes to other evidence that later eventually leads to a treatment for humans
(an indirect benefit to humans)?
Pediatricians 2/43 (5%) 20/43 (47%) 14/43 (33%) 7/43 (16%) 0
Nurses/RTs 0 24/68 (35%) 36/68 (53%) 8/68 (12%) 0
Is it your impression that animal researchers claim to the public that there are large benefits to humans from their research?
Pediatricians 4/43 (9%) 18/43 (42%) 17/43 (40%) 4/43 (9%) 0
Nurses/RTs 15/68 (22%) 34/68 (50%) 17/68 (25%) 2/68 (3%) 0
Some people argue that animal research rarely produces benefits to humans. Do you agree that this is likely?a
Strongly Agree Agree Uncertain Disagree Strongly Disagree
Pediatricians 0 7/43 (16%) 5/43 (12%) 23/43 (54%) 8/43 (19%)
Nurses/RTs 2/68 (3%) 7/68 (10%) 37/68 (54%) 19/68 (28%) 3/68 (4%)
aThere was a statistically significant (p < 0.001) difference in response between pediatricians versus nurses/RTs to the question “Some people argue that animal
research rarely produces benefits to humans. Do you agree that this is likely?”
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work in humans. Nurses were more uncertain whether
AR “rarely produces benefits to humans”, and would be
less supportive of AR if it accurately predicted effects in
humans <20% of the time.
Discussion
There are several important findings from this survey.
First, most HCW respondents expect that AR is done with
high methodological quality, and that costs and difficulty
are not acceptable justifications for lower quality. Most ex-
pect that guidelines for AR funded with public money
should be consistent with these expectations. Second, most
respondents thought that there are either sometimes or
often large benefits to humans from AR. Most disagreed
that “AR rarely produces benefit to humans.” Third,
most respondents expect that AR findings should trans-
late to humans at least 41% of the time, with many
expecting this at least 61% of the time. This includes AR
findings of adverse events (toxicity), carcinogenicity and
teratogenicity, and disease treatments. The majority
thought misleading AR results should occur no more
often than 20% of the time. If translation from AR to
humans was to occur <20% of the time, most would be
less supportive of AR. Finally, most respondents expect
that AR findings should be reproducible between la-
boratories and between strains of the same species.
There are important implications of these findings for
public and HCW acceptance of AR (Table 5).
Table 4 Healthcare worker expectations for translation to humans from animal research paid for with public funding
Statement about an expectation from animal research
Respondent Group 5-20% 21-40% 41-60% 61-80% >80%
Drugs tested on animals should correctly predict adverse reactions in humans at least what percent of the time?
Pediatricians 4/42 (10%) 9/42 (21%) 9/42 (21%) 13/42 (31%) 7/42 (17%)
Nurses/RTs 3/67 (5%) 7/67 (10%) 14/67 (21%) 18/67 (27%) 25/67 (37%)
Drugs that work well in animal experiments should prove to work in humans for the same disease at least what percent of the time?
Pediatricians 5/42 (12%) 11/42 (26%) 8/42 (19%) 14/42 (33%) 4/42 (10%)
Nurses/RTs 3/67 (5%) 9/67 (13%) 10/67 (15%) 19/67 (28%) 26/67 (39%)
For an animal research result to be credible, a second laboratory should be able to reproduce the results from the first laboratory at least what
percent of the time?
Pediatricians 0 0 2/42 (5%) 8/42 (19%) 32/42 (76%)
Nurses/RTs 0 1/67 (2%) 4/67 (6%) 11/67 (16%) 51/67 (76%)
Drugs tested on animals should correctly predict drugs that cause cancer or birth defects in humans at least what percent of the time?
Pediatricians 3/42 (7%) 8/42 (19%) 5/42 (12%) 15/42 (36%) 11/42 (26%)
Nurses/RTs 2/67 (3%) 5/67 (8%) 11/67 (16%) 21/67 (31%) 28/67 (42%)
Drugs that work well in experiments in one type of animal should prove to work well in another closely related animal (for example, in different
types of rats) at least what percent of the time?
Pediatricians 2/41 (5%) 2/41 (5%) 9/41 (22%) 12/41 (29%) 16/41 (39%)
Nurses/RTs 0 0 11/67 (16%) 19/67 (28%) 37/67 (55%)
Drugs that work well in animals with stroke, severe infection, cancer, brain or spinal cord injury should work in humans at least what percent of the
time?a
Pediatricians 5/41 (12%) 12/41 (29%) 5/41 (12%) 13/41 (32%) 6/41 (15%)
Nurses/RTs 4/66 (6%) 4/66 (6%) 9/66 (14%) 23/66 (35%) 26/66 (39%)
Experiments sometimes find a drug beneficial in animals when it is harmful in humans; and, sometimes find a drug harmful in animals when it is
beneficial in humans. These misleading animal experiments should occur at most what percent of the time?
Pediatricians 24/42 (57%) 12/42 (29%) 5/42 (12%) 1/42 (2%) 0
Nurses/RTs 38/67 (57%) 19/67 (28%) 6/67 (9%) 3/67 (5%) 1/67 (2%)
Assume drugs studied in animals accurately predict effects in humans less than 20% of the time. If this were true, it would significantly reduce your
support for animal research.a
Strongly Agree Agree Uncertain Disagree Strongly Disagree
Pediatricians 7/42 (17%) 13/42 (31%) 5/42 (12%) 11/42 (26%) 6/42 (14%)
Nurses/RTs 40/67 (60%) 16/67 (24%) 7/67 (10%) 2/67 (3%) 2/67 (3%)
aThere was a statistically significant (p < 0.001) difference in response between pediatricians versus nurses/RTs to the two questions: “Drugs that work well in
animals with stroke, severe infection, cancer, brain or spinal cord injury should work in humans at least what percent of the time?” and “Assume drugs studied in
animals accurately predict effects in humans less than 20% of the time. If this were true, it would significantly reduce your support for animal research.”
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Previous public surveys have generally asked only
whether people support AR for human benefit, and not
asked people to evaluate the details of their expectations
of AR. For example, the Eurobarometer asks “scientists
should be allowed to experiment on animals like dogs
and monkeys if this can help sort out human health
problems”; in 2010, 44% of Europeans responded ‘agree’
and 37% ‘disagree’ [44]. This support for AR was linked
with “greater appreciation of the contributions of science
to the quality of life” and “an omnipotent vision of sci-
ence” [45]. In the UK the 2012 Ipsos MORI determined
that most (85%) are ‘conditional acceptors’ of AR; people
accept AR “so long as it is for medical research pur-
poses”, “for life-threatening diseases”, “so long as there is
no unnecessary suffering”, or “where there is no alterna-
tive”, considering AR as a “necessary evil” for human
benefit [41]. In the United States the 2011 Gallup’s
Values and Beliefs survey found that when asked
whether medical testing on animals is morally acceptable
or morally wrong, 43% (and 54% of young adults 18-
29 yr old) responded ‘morally wrong’ [46]. In a survey in
Sweden including patients with rheumatoid arthritis and
scientific expert members of research ethics boards,
most respondents agreed to AR for at least some type of
biomedical research. Support was highest for AR into “fatal
diseases” (83.1%), and diseases with “insufficient treatment
options” (82.1%) [47]. In a UK survey of scientists promot-
ing AR, lay public, and animal welfarists, the support for
AR (on a Likert scale of 7) was 5.33 (1.46), 3.57 (1.70), and
1.48 (0.87) respectively. Scientists and lay public supported
animal use only for “medical research”, and not for dissec-
tion, personal decoration, or entertainment [48]. These
surveys suggest people support AR on the understanding
that it is necessary to provide significant benefit for
humans with severe diseases, and is done to high ethical
standards. However, none asked for the amount of detail as
in our survey.
Some qualitative research also suggests there is condi-
tional public acceptance of AR based on a utilitarian
analysis of costs (to animals) and benefits (to humans)
[49,50]. This conditional acceptance is usually based on
the assumption that regulation has assured AR is to high
animal welfare standards, of high scientific validity and
merit (i.e., high quality research, leading to human bene-
fit and cures), and that there are not alternative research
methods [49-51]. Scientists understand this role of
Table 5 Possible important implications of the findings from this survey
Respondents’ expectation Published empirical evidence Possible implication(s)
AR is done using the best known methods:
high standards of animal welfare.a
Compatible with recommendations of recent
guidelines from the UK, USA, and Canada [63-65].
Studies have found poor reporting of animal welfare,
including poor attention to pain control, and not using
the most acceptable methods of euthanasia [11,12].
AR may need to be of much higher animal
welfare quality in order to maintain public
and HCW support.
AR is done using the best known methods:
high standards of methodological quality.b
Compatible with recommendations of recent
guidelines from the UK, US, and Canada [63-65].
Studies have found poor methodological quality of
AR in multiple research areas, including after
publication of the ARRIVE guidelines [6-12].
AR may need to be of much higher
methodological quality in order to maintain
public and HCW support.
AR often produces benefit to humans. Press releases by academic medical centers often
promote AR, and most claim relevance to human
health without caveats about extrapolating results to
people [66]. Of published basic research papers,
0.004% led to the development of a clinically useful
class of drugs [67].
Most HCW may not be aware of the
literature regarding translation of AR.
AR has high translation rates of findings to
humans, including in the areas of toxicology,
carcinogenicity, teratogenicity, and therapeutic
success.c
Translation rates from AR to humans are at best
0-5% in the fields of sepsis, stroke, spinal cord
injury, traumatic brain injury, cancer, degenerative
brain diseases, acquired immunodeficiency
syndrome, asthma, and others [16-32]. Pharmaceutical
drug development translation from AR to humans
is about 8% [33,34]. Reviews of high impact published
AR have found translation rates are at best
1-10% [15-18,67-69].
AR may need to be much better at
predicting human responses to drugs and
disease in order to maintain public and
HCW support.
AR: animal research; HCW: health care workers.
a For example, monitoring and titration of anesthesia, monitoring and titration of pain control even over-night, using the most humane known methods of eu-
thanasia, avoiding stressed animals, and using the fewest number of animals possible.
b For example, performing a systematic literature review to inform study design, using optimal design including randomization and blinding, attention to training
of staff, and to choosing models that have shown translation of findings to humans.
c For example, most think translation rate should be over 40%, that misleading results for humans should occur no more than 20% of the time, and that if this
was not the case their support for AR would be significantly reduced.
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regulation as leading to societal acceptance of AR, and
see regulation as legitimating AR practice [51-53]. How-
ever, our survey suggests that this trust in regulation
may be misplaced, because regulation does not result in
AR that meets HCW expectations for animal welfare,
methodological quality, human benefit, or rates of trans-
lation to human medicine and cures (Table 5). Moreover,
these studies showed that the public is far less accepting
of the use of genetically modified animals in research,
based on a deontological approach where this AR is seen
as ‘wrong’ [49,50]. We did not ask about the common
use of genetically modified animals in AR, and therefore
may have underestimated HCW expectations of AR.
There are two main explanations for the poor predict-
ive accuracy of AR for humans. First, it is possible that
the poor methodological quality of AR has resulted in a
biased literature that has led to many human trials based
on inappropriate data. Second, it is possible that animal
models are not good ‘causal analogical models’; not use-
ful to extrapolate findings to humans because there are
major causal disanalogies between species [54,55]. Ani-
mal models are based on this reasoning: when an animal
model is similar to the human with respect to traits/
properties a,b,c [e.g. fever, hypotension, and kidney in-
jury in sepsis], and when the animal model is found to
have property d [e.g. response to protein-C treatment],
then it is inferred that the human also likely has prop-
erty d. This ‘causal analogy’ assumes that there are few
causal disanalogies: few properties e,f,g that are unique
to either the animal or human and that interact causally
with the common properties a,b,c. However, animals are
evolved complex systems; they have a myriad of interact-
ing modules at hierarchical levels of organization [56].
As a result of this complexity, animals have emergent
properties [e.g. animal traits/functions, like property d]
that are dependent on initial conditions [e.g. gene ex-
pression profiles, the context of the organism, like prop-
erties a,b,c, and e,f,g]. In complex systems [e.g. animals],
very small differences in initial conditions [e.g. properties
e,f,g specific to a species/strain] can result in dramatic dif-
ferences in response to the same perturbation [e.g. drug,
treatment, or disease leading to property d] [54-58]. There
is much empirical data finding major causal disanalogies
between animal species: differences in gene expression at
baseline and in response to perturbations, and in disease
susceptibilities [59-62]. Thus, complexity science suggests
there may be an in principle limitation for AR to predict
human responses. Our survey suggests that these compet-
ing explanations must be sorted out to determine whether
translation can meet public expectations in weighing the
costs and benefits of AR.
This study has several limitations. Response rates for
pediatricians and nurses/RTs were 39% and 58% respect-
ively; thus we cannot rule out biased participation in the
survey. Statements presented needed to be short and
concise, and this may have left out important details that
would have influenced the understanding of and re-
sponse to the text. The moderate sample size from one
University limits the generalizability of our results.
Nevertheless, this is the first survey we are aware of that
asks any group not just to consider whether they sup-
port AR; rather, to consider in detail the expectations for
the methodology and translation of AR. Strengths of this
study include the rigorous survey development process,
and the inclusion of the most common critiques of the
empirical practice of AR. Future study should determine
the generalizability of our results.
Conclusion
We found HCW respondents had high expectations for
the methodological quality of AR, and the translation of
findings from AR to human responses to drugs and dis-
ease. These expectations are far higher than the empir-
ical data show having been achieved. This disconnect
between HCW expectations of AR and the empirical
reality of AR suggests that if HCW were better informed
they would likely withdraw their conditional support of
AR. Improved methodological quality is an achievable
goal if this is prioritized by researchers, reviewers, edi-
tors, and funders. Whether methodologically optimal AR
can achieve better human translation to meet HCW ex-
pectations is an open question.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ARJ contributed to conception and design, acquisition, analysis and
interpretation of data, and drafted the paper, and had final approval of the
version to be published. MB contributed to design, acquisition and
interpretation of data, and revising the manuscript critically for intellectual
content, and had final approval of the version to be published. NA
contributed to design, and interpretation of data, and revising the
manuscript critically for intellectual content, and had final approval of the
version to be published. NN contributed to design, and interpretation of
data, and revising the manuscript critically for intellectual content, and had
final approval of the version to be published. ARJ had full access to all the
data in the study and takes responsibility for the integrity of the data and
the accuracy of the data analysis. All authors agree to be accountable for all
aspects of the work.
Acknowledgements
MB was supported for this research by a summer studentship from Alberta
Innovates Health Solutions; the funding agency had no role in the design
and conduct of the study; collection, management, analysis or interpretation
of the data; preparation, review, or approval of the manuscript; or the
decision to submit the manuscript for publication.
Author details
1Department of Pediatrics, University of Alberta, Edmonton Clinic Health
Academy, 4-546 11405 87 Ave, Edmonton, AB, Canada. 2John Dossetor
Health Ethics Center, University of Alberta, Edmonton, AB, Canada. 3Faculty
of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
4Department of Philosophy, Morehouse College, Atlanta, GA, USA.
5Community Health & Preventive Medicine, Morehouse School of Medicine,
Atlanta, GA, USA.
Joffe et al. BMC Medical Ethics  (2015) 16:29 Page 8 of 10
Received: 14 November 2014 Accepted: 27 April 2015
References
1. National Research Council Committee on Recognition and Alleviation of
Distress in Laboratory Animals. Recognition and alleviation of distress in
laboratory animals. Washington, DC: National Academies Press; 2008.
2. National Research Council Committee on recognition and alleviation of
pain in laboratory animals. Recognition and alleviation of pain in laboratory
animals. Washington DC: National Academies Press; 2009.
3. Rollin BE. Animal research: a moral science. EMBO Rep. 2007;8(6):521–5.
4. Robert B. Lives in the balance: utilitarianism and AR. In: Garrett JR, editor. The
ethics of animal research: exploring the controversy. USA: MIT; 2012. p. 81–105.
5. Matthews RAJ. Medical progress depends on animal models- doesn’t it? J R
Soc Med. 2008;101(2):95–8.
6. Bara M, Joffe AR. The methodological quality of animal research in critical
care: the public face of science. Annals Intensive Care. 2014;4:26.
7. Killkenny C, Parsons N, Kadyszewski E, Festing MFW, Cuthill IC, Fry D, et al.
Survey of the quality of experimental design, statistical analysis and
reporting of research using animals. PLoS One. 2009;4(11):e7284.
8. Sena E, van der Worp B, Howells D, Macleod M. How can we improve the
preclinical development of drugs for stroke? Trends Neurosci. 2007;30:433–9.
9. Baginskait J. Scientific Quality Issues in the Design and Reporting of
Bioscience Research: A Systematic Study of Randomly Selected Original In
Vitro, In Vivo and Clinical Study Articles Listed in the PubMed Database. In
CAMARADES Monogr 2012. [http://www.dcn.ed.ac.uk/camarades/files/
Camarades%20Monograph%20201201.pdf ].
10. Baker D, Lidster K, Sottomayor A, Amor S. Two years later: journals are not
yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical
animal studies. PLoS Biol. 2014;12(1):e1001756.
11. Bara M, Joffe AR. The ethical dimension in published animal research in
critical care: the public face of science. Crit Care. 2014;18(1):R15.
12. Carbone L. Pain in laboratory animals: the ethical and regulatory imperatives.
PLoS One. 2011;6:e21578.
13. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design,
power, and interpretation of studies in the standard murine model of ALS.
Amyotroph Lateral Scler. 2008;9:4–15.
14. Steward O, Popovich PG, Dietrich WD, Kleitman N. Replication and
reproducibility in spinal cord injury research. Exp Neurol. 2012;233:597–605.
15. Horrobin DF. Modern biomedical research: an internally self-consistent universe
with little contact with medical reality. Nat Rev Drug Discov. 2003;2:151–4.
16. Pippin JJ. AR in medical sciences: seeking a convergence of science, medicine,
and animal law. South Texas Law Rev. 2013;54:469–511.
17. Shanks N, Greek R, Greek J. Are animal models predictive for humans? Phil
Ethics Humanities Med. 2009;4:2.
18. Pound P, Bracken MB. Is AR sufficiently evidence based to be a cornerstone
of biomedical research? BMJ. 2014;348:g3387.
19. Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy
fail to translate to the clinical setting. Crit Care Med. 2009;37(Suppl):S30–7.
20. Opal SM, Patrozou E. Translational research in the development of novel
sepsis therapeutics: logical deductive reasoning or mission impossible? Crit
Care Med. 2009;37(Suppl):S10–5.
21. Fink MP. Animal models of sepsis. Virulence. 2013;5(1):143–53.
22. Jauch EC, Saver JL, Adams HP, Bruno Jr A, Connors JJ, Demaerschalk BM,
et al. Guidelines for the early management of patients with acute ischemic
stroke: a guideline for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke. 2013;44:870–947.
23. Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C.
Neuroprotection for ischemic stroke: translation from the bench to the
bedside. Int J Stoke. 2012;7:407–18.
24. Akhtar AZ, Pippin JJ, Sandusky CB. Animal models of spinal cord injury: a
review. Rev Neurosci. 2009;19:47–60.
25. Domingo A, Al-Yahya AA, Asiri Y, Eng JJ, Lam T. A systematic review of the
effects of pharmacological agents on walking function in people with spinal
cord injury. J Neurotrauma. 2012;29:865–79.
26. Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury.
Nat Rev Neurosci. 2013;14:128–42.
27. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer
research. Nature. 2012;483:531–3.
28. Hutchinson L, Kirk R. High drug attrition rates- where are we going wrong?
Nat Rev Clin Oncol. 2011;8:189.
29. Ransohoff RM. Animal models of multiple sclerosis: the good, the bad and
the bottom line. Nat Neurosci. 2012;15:1074–7.
30. Geerts H. Of mice and men: bridging the translational disconnect in CNS
drug discovery. CNS Drugs. 2009;23(11):915–26.
31. Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nat Rev
Microbiol. 2012;10:852–67.
32. Holmes AM, Solari R, Holgate ST. Animal models of asthma: value,
limitations and opportunities for alternative approaches. Drug Discov Today.
2011;16(15–16):659–70.
33. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical
R&D. Nat Rev Drug Discov. 2011;10:428–38.
34. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with
new drug development: success rates for investigational drugs. Clin
Pharmacol Ther (St Louis, MO, U S). 2010;87(3):272–7.
35. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
Chemoinformatics analysis of assertions mined from literature that describe
drug-induced liver injury in different species. Chem Res Toxicol.
2010;23:171–83.
36. Hartung T. Toxicology for the twenty-first century. Nature. 2009;460:208–12.
37. Knight A. The costs and benefits of animal experiments. UK: Palgrave
Macmillan; 2011.
38. Card JW, Fikree H, Haighton LA, Lee-Brotherton V, Wan J, Sangster B. Lack of
human tissue-specific correlations for rodent pancreatic and colorectal carcinogens.
Reg Toxicol Pharm. 2012;64:442–58.
39. Knight A, Bailey J, Balcombe J. Animal carcinogenicity studies: 1. Poor
human predictivity. Altern Lab Anim. 2006;34:19–27.
40. Greek R, Shanks N, Rice MJ. The history and implications of testing
thalidomide on animals. J Philos Sci Law. 2011;11:1–32. http://jpsl.org/
archives/history-and-implications-testing-thalidomide-animals/.
41. Ipsos MOR. Views on the use of animals in scientific research. Dept for Business
Innovation & Skills; 2012. [file:///C:/DOCUME~ 1/arijoffe/LOCALS ~ 1/Temp/
1512_sri-BIS_animal_research_2012_final_report_September_published_final.pdf]
42. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
Electronic Data Capture (REDCap)- a meta-data driven methodology and
workflow process for providing translational research informatics support.
J Biomed Inform. 2009;42(2):377–81.
43. Burns KEA, Duffett M, Kho ME, Meade MO, Adhikari NKJ, Sinuff T, et al. A
guide for the design and conduct of self-administered surveys of clinicians.
CMAJ. 2008;179(3):245–52.
44. European Commission. Eurobarometer: science and technology report:
European Commission, June 2010: 60–64. [http://ec.europa.eu/public_opinion/
archives/ebs/ebs_340_en.pdf]
45. CrettazvonRoten F. European attitudes towards animal research: overview
and consequences for science. Sci Technol Soc. 2009;14(2):349–64.
46. Goodman JR, Borch CA, Cherry E. Mounting opposition to vivisection.
Contexts. 2012;11(2):68–9.
47. Masterton M, Renberg T, Sporrong SK. Patients’ attitudes towards animal
testing: ‘To conduct research on animals is, I suppose, a necessary evil’.
BioSocieties. 2014;9:24–41.
48. Knight S, Vrij A, Bard K, Brandon D. Science versus human welfare?
Understanding attitudes toward animal use. J Soc Issues. 2009;65(3):463–83.
49. Ormandy EH, Schuppli CA, Weary DM. Public attitudes toward the use of
animals in research: effects of invasiveness, genetic modification and
regulation. Anthropozoos. 2013;26(2):165–84.
50. Macnaghten P. Animals in their nature: a case study on public attitudes to
animals, genetic modification and ‘nature’. Sociology. 2004;38(3):533–51.
51. Hobson-West P. Ethical boundary-work in the animal research laboratory.
Sociology. 2012;46(4):749–663.
52. Hobson-West P. The role of ‘public opinion’ in the UK animal research
debate. J Med Ethics. 2010;36:46–9.
53. Hobson-West P. What kind of animal is the ‘Three Rs’? ATLA.
2009;37(Suppl2):95–9.
54. Greek R, Rice MJ. Animal models and conserved processes. Theor Biol Med
Model. 2012;9:40.
55. Greek R, Hansen LA. Questions regarding the predictive value of one
evolved complex adaptive system for a second: exemplified by the SOD1
mouse. Progress Biophysics Mol Biol. 2013;113:231–53.
56. Ahn AC, Tewari M, Poon C, Phillips RS. The limits of reductionism in
medicine: could systems biology offer an alternative? PLoS Med.
2006;3(6):e208.
57. Mazzocchi F. Complexity in biology. EMBO Rep. 2008;9(1):10–4.
Joffe et al. BMC Medical Ethics  (2015) 16:29 Page 9 of 10
58. Wagner A. Causality in complex systems. Biol Philos. 1999;14:83–101.
59. Seok J, Warren S, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic
responses in mouse models poorly mimic human inflammatory diseases.
Proc Natl Acad Sci U S A. 2013;110:3507–12.
60. Gentile LF, Nacionales DC, Lopez C, Vanzant E, Cuenca A, Cuenca AG, et al.
A better understanding of why murine models of trauma do not
recapitulate the human syndrome. Crit Care Med. 2014;42(6):1406–13.
61. Brawand D, Soumillon M, Necsulea A, Julien P, Csardi G, Harrigan P, et al.
The evolution of gene expression levels in mammalian organs. Nature.
2011;478:343–8.
62. Varki NM, Strobert E, Dick Jr EJ, Benirschke K, Varki A. Biomedical differences
between human and nonhuman hominids: potential roles for uniquely
human aspects of sialic acid biology. Annual Rev Pathol Mechanisms Dis.
2011;6:365–93.
63. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving
bioscience research reporting: the ARRIVE guidelines for reporting animal
research. PLoS Biol. 2010;8(6):e1000412.
64. Institute for Laboratory Animal Research: National Research Council.
Guidance for the Description of Animal Research in Scientific Publications.
Washington DC: National Academy of Sciences; 2011.
65. Canadian Council on Animal Care in Science. CCAC Guidelines on: Animal
use Protocol Review. Ottawa: Canadian Council on Animal Care; 1997
http://www.ccac.ca/Documents/Standards/Guidelines/Protocol_Review.pdf.
66. Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ. Press releases
by academic medical centers: not so academic? Ann Intern Med.
2009;150:613–8.
67. Contopoulos-Ioannidis DG, Ntzani EE, Ioannidis JPA. Translation of highly
promising basic science research into clinical applications. Am J Med.
2003;114:477–84.
68. Hackam DG, Redelmeier DA. Translation of research evidence from animals
to humans. JAMA. 2006;296(14):1731–2.
69. Knight A. Systematic reviews of animal experiments demonstrate poor
contributions to human healthcare. Rev Recent Clin Trials. 2008;3(2):89–96.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Joffe et al. BMC Medical Ethics  (2015) 16:29 Page 10 of 10
